Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma

Author(s):  Teeranachaideekul Veerawat, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn

Issue:  Jan/Feb 2021 - Volume 25, Number 1
View All Articles in Issue

Page(s):  62-72

Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 1
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 2
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 3
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 4
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 5
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 6
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 7
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 8
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 9
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 10
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma Page 11

Download in electronic PDF format for $75

Abstract:  Concentrated 7% w/w a-arbutin cream was formulated and evaluated using O/W and W/O emulsion bases as an extemporaneous preparation for melasma treatment. Cream bases were formulated with two pH values, 4.0 and 5.5, using a hot process. The stability of the creams was studied for 60 days under three storage conditions (i.e., 2°C to 8°C, 30°C, 40°C). Cream characteristics and all aspects of product stability including physical, chemical, and microbial were investigated. Stability was defined as no dramatic change in color, viscosity, pH, and no visible microbial growth. For stability, at least 90% of the initial a-arbutin concentration quantified by stability-indicating high-performance liquid chromatography must be obtained. It was found that pH had no influence on the a-arbutin or formulations’ stability. All formulations had a-arbutin remaining higher than 90% (approximately 92%) after being stored for 60 days in all storage conditions with no significant changes in pH or viscosity. All samples complied with the microbial limits test for nonsterile pharmaceutical preparation for cutaneous products. However, a color change was detected in O/W and W/O emulsions, especially at 40°C storage condition within 28 and 14 days, respectively. Drug crystals were observed in W/O emulsion stored at 2°C to 8°C. Concerning the in vitro drug release, a-arbutin was released from O/W emulsion but not from W/O emulsion. From the above results, the O/W emulsion that was developed in this study can be used as a cream base for concentrated a-arbutin as an extemporaneous preparation. The developed a-arbutin cream prepared using O/W emulsions can be used as an extemporaneous preparation with a beyond-use date of 60 days when stored at room temperature (30°C) and in the refrigerator (2°C to 8°C).

Related Keywords: α-arbutin, alpha arbutin cream, hydroquinone derivative, tyrosinase inhibitor, melanin, topical preparations, melasma, skin pigment disorders, hyperpigmentation, physical stability, chemical stability, microbial growth

Related Categories: LEGAL, PEER-REVIEWED, SUPPORT, QUALITY CONTROL

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Teeranachaideekul Veerawat
, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
Jan/Feb 2021
Pg. 62-72

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A
, Fokken Dawn
Sep/Oct 2009
Pg. 386-389

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Heustess Allie
, Asbill Scott, Eagerton David, Arnold John
Nov/Dec 2014
Pg. 512-515

Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream
Polonini Hudson C
, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B
Jul/Aug 2014
Pg. 332-340

Deoxyarbutin 3% Anhydrous Emulsion
Allen Loyd V Jr
Jan/Feb 2022
Pg. 54

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Basics of Compounding for Dry-Skin Conditions
Allen Loyd V Jr
Nov/Dec 2003
Pg. 460-463

View Sample
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
Nov/Dec 2020
Pg. 446-448

Nondetergent Neutral Dry Skin Cream
Allen Loyd V Jr
Sep/Oct 2007
Pg. 425

Physicochemical Stability of Compounded Creams Containing alpha-Hydroxy Acids
de Villiers Melgardt M
, Narsai Kirti, van der Watt Jakkie G
Jan/Feb 2000
Pg. 72-75

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream)
Allen Loyd V Jr
Jul/Aug 2020
Pg. 320

Topical Oil-in-Water Cream Bases, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2002
Pg. 303-304

Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Polonini Hudson C
, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
Jul/Aug 2021
Pg. 336-343

Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women
Mason Dave
Jul/Aug 2002
Pg. 255-256

Breast Care Cream
Allen Loyd V Jr
Nov/Dec 2007
Pg. 505

Progesterone 10% Cream
Allen Loyd V Jr
Sep/Oct 2016
Pg. 412

Return to Top